** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to "market perform" from "outperform," cuts PT to $4 from $5
** Cites "uncertainties" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine
** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared
** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate
** Six of seven analysts rate CMPX stock "buy" or higher and one "hold"; their median PT is $7.50 - LSEG
** As of last close, CMPX stock has risen 1.9% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.